Vitruvias Therapeutics is a private generic pharmaceutical company focused on technically difficult sterile injectable products. The company develops, manufactures, and markets products via domestic and international partnerships. Vitruvias received its first ANDA approval in September 2017 and expects to launch that product in early 2018. It has several other ANDAs either filed with the FDA or in various stages of development. The company will use the recent financing to complete multiple projects already under development. Leadership includes President Carl Whatley, Bryce Harvey, and Roger Graben, PhD, who previously founded and built ProEthic Pharmaceuticals and Midlothian Laboratories.

Total raised

$12M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2018